Canada markets closed

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.55+0.17 (+3.16%)
At close: 04:00PM EDT
5.63 +0.08 (+1.44%)
After hours: 06:36PM EDT

Applied Therapeutics, Inc.

545 Fifth Avenue
Suite 1400
New York, NY 10017
United States
212 220 9226

Full Time Employees26

Key Executives

NameTitlePayExercisedYear Born
Dr. Shoshana Shendelman Ph.D.Chair of the Board of Directors, Founder, President, CEO & Secretary946.08kN/A1979
Mr. Les D. FuntleyderCFO, Principal Financial Officer & Independent Director48.75kN/A1971
Dr. Riccardo Perfetti M.D., Ph.D.Chief Medical Officer860.76kN/A1961
Mr. Constantine ChinoporosCOO & Chief Business OfficerN/AN/A1966
Ms. Catherine ThorpeChief Accounting OfficerN/AN/A1964
Mr. Corwin Dale HooksChief Commercial OfficerN/AN/A1967
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Corporate Governance

Applied Therapeutics, Inc.’s ISS Governance QualityScore as of July 1, 2024 is 10. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 7; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.